IL13RA2 and neoplasm: One ongoing phase 1 clinical trial investigates the safety, efficacy, and feasibility of IL13Ra2 as a potential CAR T‐cell target [8] in patients with recurrent or refractory malignant GBM due to its specificity for GBM tumor cells and limited expression on normal brain cells (NCT02208362).